• A Phase I/II clinical-stage drug
   
• Active against TdT-positive leukemias
   
• IP: Patent protection through 2014
   
• Next generation analogs: 2023
   
• Status: Phase I/II clinical trial on-going at two sites in the US
   
• Orphan Drug Designation obtained
   
• Relevant Biomarker: TdT
   
• Estimated Market Potential: >$350M
   

Cordycepin (3’-deoxyadenosine), a nucleoside analog, is OncoVista’s first clinical-stage development compound.

The compound was obtained through a merger with Aengus Pharmaceuticals which was completed in January 2006.

Cordycepin is a Phase I/II clinical stage drug candidate for treatment of refractory Acute Lymphoblastic Leukemia (ALL) patients who express the enzyme terminal deoxynucleotidyl transferase (TdT).

A Phase I/II clinical trial is currently enrolling and treating patients at two sites in the US: Dana Farber Cancer Institute (Boston MA) and the Cancer Treatment and Research Center (San Antonio TX)